{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:49:47Z","timestamp":1782787787777,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018313","name":"Cleveland Eye Bank Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["VR210001"],"award-info":[{"award-number":["VR210001"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["P30-EY025585"],"award-info":[{"award-number":["P30-EY025585"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.biopha.2025.117857","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T18:58:26Z","timestamp":1737140306000},"page":"117857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Insights from animal studies exploring the efficacy and safety of topical losartan, in prophylaxis and treatment of corneal scarring fibrosis"],"prefix":"10.1016","volume":"183","author":[{"given":"Valeria","family":"Villabona-Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Araujo Lima","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8121-960X","authenticated-orcid":false,"given":"Steven E.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.117857_bib1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.biopha.2025.117857_bib2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bjophthalmol-2011-300539","article-title":"Global estimates of visual impairment: 2010","volume":"96","author":"Pascolini","year":"2012","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.117857_bib3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ophtha.2023.03.012","article-title":"Global trends in blindness and vision impairment resulting from corneal opacity 1984\u20132020","volume":"130","author":"Wang","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2025.117857_bib4","series-title":"Ophthalmology","article-title":"Corneal opacity in the United States: An American Academy of Ophthalmology IRIS\u00ae Registry (Intelligent Research in Sight) study","author":"Singh","year":"2024"},{"key":"10.1016\/j.biopha.2025.117857_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2021.09.010","article-title":"The economic burden of vision loss and blindness in the United States","volume":"129","author":"Rein","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2025.117857_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/jamaophthalmol.2015.4776","article-title":"Global survey of corneal transplantation and eye banking","volume":"134","author":"Gain","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.biopha.2025.117857_bib7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2147\/OPTH.S142702","article-title":"Awareness and attitudes toward corneal donation: challenges and opportunities","volume":"12","author":"Williams","year":"2018","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.117857_bib8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jcrs.2010.12.037","article-title":"Anatomy and physiology of the cornea","volume":"37","author":"DelMonte","year":"2011","journal-title":"J. Cat. Refract Surg."},{"key":"10.1016\/j.biopha.2025.117857_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/iovs.63.1.22","article-title":"Corneal opacity: cell biological determinants of the transition from transparency to transient haze to scarring fibrosis, and resolution, after injury","volume":"63","author":"Wilson","year":"2022","journal-title":"Invest Opthalmol Vis. Sci."},{"key":"10.1016\/j.biopha.2025.117857_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108089","article-title":"Corneal wound healing","volume":"197","author":"Wilson","year":"2020","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.117857_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/exer.1994.1081","article-title":"Epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, acidic fibroblast growth factor, basic fibroblast growth factor, and interleukin-1 proteins in the cornea","volume":"59","author":"Wilson","year":"1994","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.117857_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/jop.2022.0174","article-title":"Topical losartan: Practical guidance for clinical trials in the prevention and treatment of corneal scarring fibrosis and other eye diseases and disorders","volume":"39","author":"Wilson","year":"2023","journal-title":"J. Ocul. Pharm. Ther."},{"key":"10.1016\/j.biopha.2025.117857_bib13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.11.7.9","article-title":"Topical losartan and corticosteroid additively inhibit corneal stromal myofibroblast generation and scarring fibrosis after alkali burn injury","volume":"11","author":"Sampaio","year":"2022","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.biopha.2025.117857_bib14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1006\/exer.2002.2066","article-title":"TGF\u03b2 induced myofibroblast differentiation of rabbit keratocytes requires synergistic TGF\u03b2, PDGF and integrin signaling","volume":"75","author":"Jester","year":"2002","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.117857_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3928\/1081597X-20211007-02","article-title":"Epithelial basement membrane regeneration after PRK-induced epithelial-stromal injury in rabbits: fibrotic versus non-fibrotic corneal healing","volume":"38","author":"De Oliveira","year":"2022","journal-title":"J. Refract Surg."},{"key":"10.1016\/j.biopha.2025.117857_bib16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3928\/1081597X-20190625-02","article-title":"Coordinated modulation of corneal scarring by the epithelial basement membrane and Descemet\u2019s basement membrane","volume":"35","author":"Wilson","year":"2019","journal-title":"J. Refract Surg."},{"key":"10.1016\/j.biopha.2025.117857_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108272","article-title":"Corneal myofibroblasts and fibrosis","volume":"201","author":"Wilson","year":"2020","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.117857_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108594","article-title":"TGF beta \u22121, \u22122 and \u22123 in the modulation of fibrosis in the cornea and other organs","volume":"207","author":"Wilson","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.biopha.2025.117857_bib19","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.bbrc.2014.03.014","article-title":"Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-\u03b2-induced phosphorylation of ERK","volume":"446","author":"Wylie-Sears","year":"2014","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.biopha.2025.117857_bib20","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/02713689009069932","article-title":"Transforming growth factor-\u03b2 in human aqueous humor","volume":"9","author":"Jampel","year":"1990","journal-title":"Curr. Eye Res"},{"key":"10.1016\/j.biopha.2025.117857_bib21","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.3390\/cells11152336","article-title":"TGF-\u03b2 superfamily signaling in the eye: implications for ocular pathologies","volume":"11","author":"Hachana","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.117857_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115317","article-title":"Corneal fibrosis: from in vitro models to current and upcoming drug and gene medicines","volume":"209","author":"Trujillo Cubillo","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2025.117857_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2024.109884","article-title":"Two-phase mechanism in the treatment of corneal stromal fibrosis with topical losartan","volume":"242","author":"Wilson","year":"2024","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.117857_bib24","doi-asserted-by":"crossref","first-page":"10894","DOI":"10.1016\/j.exer.2022.108940","article-title":"Topical losartan inhibits corneal scarring fibrosis and collagen type IV deposition after Descemet\u2019s membrane-endothelial excision in rabbits","volume":"216","author":"Sampaio","year":"2022","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.117857_bib25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/ICO.0000000000003476","article-title":"Topical losartan inhibition of myofibroblast generation in rabbit corneas with acute incisions","volume":"43","author":"Martinez","year":"2024","journal-title":"Cornea"},{"key":"10.1016\/j.biopha.2025.117857_bib26","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/ICO.0000000000003527","article-title":"Topical losartan for treating corneal haze after ultraviolet-A\/riboflavin collagen cross-linking","volume":"43","author":"Rodgers","year":"2024","journal-title":"Cornea"},{"key":"10.1016\/j.biopha.2025.117857_bib27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3928\/1081597X-20221018-02","article-title":"Topical losartan for treating corneal fibrosis (haze): first clinical experience","volume":"38","author":"Pereira-Souza","year":"2022","journal-title":"J. Refract Surg."},{"key":"10.1016\/j.biopha.2025.117857_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1167\/tvst.12.9.20","article-title":"Topical losartan decreases myofibroblast generation but not corneal opacity after surface blast-simulating irregular PTK in rabbits","volume":"12","author":"Sampaio","year":"2023","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.biopha.2025.117857_bib29","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3928\/1081597X-20221026-03","article-title":"Losartan inhibition of myofibroblast generation and late haze (scarring fibrosis) after PRK in rabbits","volume":"38","author":"Sampaio","year":"2022","journal-title":"J. Refract Surg."},{"key":"10.1016\/j.biopha.2025.117857_bib30","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1167\/iovs.18-26451","article-title":"Descemet's membrane modulation of posterior corneal fibrosis","volume":"60","author":"Medeiros","year":"2019","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2025.117857_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108803","article-title":"Descemet\u2019s membrane injury and regeneration, and posterior corneal fibrosis, in rabbits","volume":"213","author":"Sampaio","year":"2021","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.117857_bib32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.exer.2005.09.021","article-title":"Stromal haze, myofibroblasts, and surface irregularity after PRK","volume":"82","author":"Netto","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.biopha.2025.117857_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3928\/1081597X-20161123-01","article-title":"Phototherapeutic keratectomy: science and art","volume":"33","author":"Wilson","year":"2017","journal-title":"J. Refract Surg."},{"key":"10.1016\/j.biopha.2025.117857_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1126\/science.1192152","article-title":"Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism","volume":"332","author":"Habashi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.biopha.2025.117857_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/tvst.13.8.22","article-title":"Effect of topical losartan in the treatment of established corneal fibrosis in rabbits","volume":"13","author":"Villabona-Martinez","year":"2024","journal-title":"Trans. Vis. Sci. Tech."},{"key":"10.1016\/j.biopha.2025.117857_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109443","article-title":"Standardization of corneal alkali burn methodology in rabbits","volume":"230","author":"Villabona-Martinez","year":"2023","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.117857_bib37","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0161-6420(97)30306-6","article-title":"Late onset corneal haze after photorefractive keratectomy for moderate and high myopia","volume":"104","author":"Lipshitz","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2025.117857_bib38","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0886-3350(00)00625-8","article-title":"Mytomycin-C for post-PRK corneal haze","volume":"26","author":"Raviv","year":"2000","journal-title":"J. Cataract Refract Surg."},{"key":"10.1016\/j.biopha.2025.117857_bib39","article-title":"Biological effects of mitomycin C on late corneal haze stromal fibrosis following PRK","volume":"200","author":"De Oliveira","year":"2020","journal-title":"Exp. Eye Res"},{"key":"10.1016\/j.biopha.2025.117857_bib40","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3928\/1081597X-20090617-10","article-title":"Impact on the corneal endothelium of mitomycin C during photorefractive keratectomy","volume":"25","author":"Roh","year":"2009","journal-title":"J. Refract Surg."},{"key":"10.1016\/j.biopha.2025.117857_bib41","first-page":"1828","article-title":"Quiescent keratocytes fail to repair MMC induced DNA damage leading to the long-term inhibition of myofibroblast differentiation and wound healing","volume":"18","author":"Jester","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.biopha.2025.117857_bib42","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/ICO.0000000000001231","article-title":"Corneal breakthrough haze after photorefractive keratectomy with mitomycin C: incidence and risk factors","volume":"36","author":"Kaiserman","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.biopha.2025.117857_bib43","unstructured":"Dutra B.A.L., Martinez V.V., Santhiago M.R., Wilson S.E. Topical losartan dosage response and corneal toxicity at higher concentrations. Cornea, in press."},{"key":"10.1016\/j.biopha.2025.117857_bib44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3928\/1081597X-20170126-02","article-title":"Regeneration of defective epithelial basement membrane and restoration of corneal transparency after photorefractive keratectomy","volume":"33","author":"Marino","year":"2017","journal-title":"J. Refract Surg."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:33:21Z","timestamp":1778513601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":44,"alternative-id":["S0753332225000514"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117857","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights from animal studies exploring the efficacy and safety of topical losartan, in prophylaxis and treatment of corneal scarring fibrosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117857"}}